Newbury Pharmaceuticals Q4 revenue more than doubles on new launches
Sweden's Newbury Pharmaceuticals said Q4 net revenue rose about 130% year on year on new product launches, Reuters reported, with EBITDA loss narrowing.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Sweden-based specialty drug maker Newbury Pharmaceuticals posted fourth-quarter net revenue that grew about 130% year on year. The company credits the increase to recent product launches and a larger presence in tenders across the Nordic region.
The quarterly EBITDA loss narrowed from a year earlier, to SEK 5.10 million. Gross margin, however, declined on product mix and price pressure in tenders. International sales stayed limited, as activity in the Middle East advanced more slowly than expected because of geopolitical factors.
The company expects its gross margin to improve in the coming quarters and has set reaching EBITDA breakeven as a priority for long-term growth. It also secured new generic approvals and exclusive rights to a hospital portfolio in Iraq, and says it still aims to launch more than 30 products in the Nordics by December 2026.
why it matters
For the broader market this is a company-level story. Investors will likely focus on the gross margin trend, the path to EBITDA breakeven, and whether Middle East sales can pick up.
tags
instruments
sources
- Sweden's Newbury Pharmaceuticals Q4 revenue more than doubles on new product launches — Reuters, 28 October 2026 at 07:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗